NRx Launches Ketamine Sales, Targets January Shipments

NRx Pharmaceuticals

WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) has begun commercial sales operations for its newly approved, U.S.-manufactured preservative-free ketamine injection, targeting a pharmaceutical market affected by supply shortages since 2018 and projecting sales margins exceeding 50%.

The Wilmington-based company deployed a 17-person national sales force this week, with initial supply agreements and preorders expected before the end of 2026. Product shipments are scheduled to begin in January 2027.

NRx said its sales representatives have established relationships with hospital purchasers and group purchasing organizations responsible for approximately 80% of U.S. ketamine sales. The figure describes the purchasing reach of those relationships rather than secured contracts or orders.

The company expects its manufacturing process and sales structure to generate gross and net sales margins above 50%, a projection based on anticipated production efficiencies and distribution costs.

NRx’s product uses blow-fill-seal manufacturing technology, which forms, fills and seals a plastic vial in a single process. The company estimates that manufacturing costs account for less than 20% of the selling price using this approach, compared with 70% or more for traditional glass-vial production based on its previous experience.

READ:  Phreesia Sets Dec. 2 Release for Quarterly Earnings

The injectable ketamine is packaged in a preservative-free vial equipped with a luer-lock connection that attaches directly to a sterile syringe, eliminating the need for a needle to withdraw medication from the container.

NRx said the design could reduce handling time, needlestick exposure and sharps waste in hospitals and other clinical settings.

“By enlisting seasoned sales representatives who already sell sterile injectable drugs, we are able to drive considerable efficiency in costs of sales and marketing,” said Jonathan Javitt, the company’s chief executive officer.

The commercial launch comes as ketamine injection products remain affected by a longstanding U.S. drug shortage. NRx is positioning domestic manufacturing and supply commitments as alternatives for hospitals seeking more predictable access to the medication.

READ:  Inhibikase Loss Widens as Phase 3 Trial Spending Doubles

The company said its product has an initial two-year expiration period, compared with shorter beyond-use periods generally applicable to compounded sterile medications.

NRx is also pursuing a regulatory challenge involving benzethonium chloride, a preservative used in existing ketamine injection formulations.

The company has filed a citizen petition asking the Food and Drug Administration to remove the preservative from ketamine products. Its supporting toxicology report raises concerns about potential exposure levels during routine clinical use.

The FDA has not determined benzethonium chloride to be generally recognized as safe and effective for over-the-counter antiseptic hand rubs, a regulatory finding that does not itself establish the safety of the ingredient in injectable ketamine.

READ:  Invenio Financial Enters Bankruptcy Market With Acquisition

NRx’s preservative-free formulation provides a commercial distinction from existing products while the agency considers the company’s petition.

The company is also expanding its manufacturing capacity beyond ketamine.

NRx said it has contracted with German equipment suppliers to double its blow-fill-seal manufacturing footprint in South Carolina, creating capacity for additional sterile injectable medicines.

The expansion is intended to support a broader portfolio of domestically manufactured injectable drugs using the same production and packaging technology.

NRx develops treatments targeting depression, post-traumatic stress disorder and suicidality. Its ketamine launch represents a commercial initiative built around an FDA-approved formulation and a manufacturing process the company intends to extend to other injectable medications.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.